A detailed history of Vident Advisory, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Vident Advisory, LLC holds 2,877 shares of BMRN stock, worth $190,256. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,877
Previous 2,717 5.89%
Holding current value
$190,256
Previous $237 Million 0.18%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$74.43 - $92.22 $11,908 - $14,755
160 Added 5.89%
2,877 $237 Million
Q1 2024

May 14, 2024

BUY
$83.81 - $99.0 $1,173 - $1,386
14 Added 0.52%
2,717 $237 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $17,606 - $22,755
231 Added 9.34%
2,703 $261 Million
Q3 2023

Feb 21, 2024

SELL
$85.07 - $94.48 $19,651 - $21,824
-231 Reduced 8.55%
2,472 $219 Million
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $210,293 - $233,554
2,472 New
2,472 $219 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.